Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Cohort Phase 2 Dose-Escalation Study of MK-7075 (Miransertib) in Proteus Syndrome

NCT04316546 is registered in ClinicalTrials.gov with National Human Genome Research Institute (NHGRI) as lead sponsor.

NCT NCT04316546
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04316546 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Cohort Phase 2 Dose-Escalation Study of MK-7075 (Miransertib) in Proteus Syndrome
Lead sponsor
National Human Genome Research Institute (NHGRI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 20, 2022
Completion date
July 1, 2028
Enrollment
38 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

proteus syndrome